TY - JOUR
T1 - T-cell receptor-like antibodies
T2 - Novel reagents for clinical cancer immunology and immunotherapy
AU - Noy, Roy
AU - Epel, Malka
AU - Haus-Cohen, Maya
AU - Klechevsky, Eynav
AU - Makler, Oryan
AU - Michaeli, Yael
AU - Denkberg, Galit
AU - Reiter, Yoram
PY - 2005/6
Y1 - 2005/6
N2 - Major histocompatibility complex class I molecules play a central role in the immune response against a variety of cells that have undergone malignant transformation by shaping the T-cell repertoire and presenting peptide antigens from endogeneous antigens to CD8+ cytotoxic T-cells. Diseased tumor or virus-infected cells are present on class I major histocompatibility complex molecule peptides that are derived from tumor-associated antigens or viral-derived proteins. Due to their unique specifity, such major histocompatibility complex-peptide complexes are a desirable target for novel approaches in immunotherapy. Targeted delivery of toxins or other cytotoxic drugs to cells which express specific major histocompatibility complex-peptide complexes that are involved in the immune response against cancer or viral infections would allow for a specific immunotherapeutic treatment of these diseases. It has recently been demonstrated that antibodies with the antigen-specific, major histocompatibility complex-restricted specificity of T-cells can be generated by taking advantage of the selection power of phage display technology. In addition to their tumor targeting capabilities, antibodies that mimic the fine specificity of T-cell receptors can serve as valuable research reagents that enable study of human class I peptide-major histocompatibility complex ligand presentation, as well as T-cell receptor peptide-major histocompatibility complex interactions. T-cell receptor-like antibody molecules may prove to be useful tools for studying major histocompatibility complex class I antigen presentation in health and disease as well as for therapeutic purposes in cancer, infectious diseases and autoimmune disorder.
AB - Major histocompatibility complex class I molecules play a central role in the immune response against a variety of cells that have undergone malignant transformation by shaping the T-cell repertoire and presenting peptide antigens from endogeneous antigens to CD8+ cytotoxic T-cells. Diseased tumor or virus-infected cells are present on class I major histocompatibility complex molecule peptides that are derived from tumor-associated antigens or viral-derived proteins. Due to their unique specifity, such major histocompatibility complex-peptide complexes are a desirable target for novel approaches in immunotherapy. Targeted delivery of toxins or other cytotoxic drugs to cells which express specific major histocompatibility complex-peptide complexes that are involved in the immune response against cancer or viral infections would allow for a specific immunotherapeutic treatment of these diseases. It has recently been demonstrated that antibodies with the antigen-specific, major histocompatibility complex-restricted specificity of T-cells can be generated by taking advantage of the selection power of phage display technology. In addition to their tumor targeting capabilities, antibodies that mimic the fine specificity of T-cell receptors can serve as valuable research reagents that enable study of human class I peptide-major histocompatibility complex ligand presentation, as well as T-cell receptor peptide-major histocompatibility complex interactions. T-cell receptor-like antibody molecules may prove to be useful tools for studying major histocompatibility complex class I antigen presentation in health and disease as well as for therapeutic purposes in cancer, infectious diseases and autoimmune disorder.
KW - Antibodies
KW - Antibody engineering
KW - Cancer immunotherapy
KW - Immunotoxins
KW - Major histocompatibility complex-peptide complex
KW - Phage display
KW - Recombinant antibodies
KW - T-cell receptor
UR - http://www.scopus.com/inward/record.url?scp=21244469866&partnerID=8YFLogxK
U2 - 10.1586/14737140.5.3.523
DO - 10.1586/14737140.5.3.523
M3 - Review article
C2 - 16250828
AN - SCOPUS:21244469866
SN - 1473-7140
VL - 5
SP - 523
EP - 536
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
IS - 3
ER -